Article Text

PDF
SHOULD GONADOTROPIN RELEASING HORMONE ANALOGUE BE ADMINISTERED TO PREVENT PREMATURE OVARIAN FAILURE IN YOUNG WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS ON CYCLOPHOSPHAMIDE THERAPY?
  1. Rajiv Sinha,
  2. Janis M Dionne
  1. Paediatric Nephrology, British Columbia’s Children’s Hospital, Vancouver, BC, Canada; rajivsinha_in@yahoo.com
  2. Paediatric Nephrology, British Columbia’s Children’s Hospital, Vancouver, BC, Canada

Statistics from Altmetric.com

A 15-year-old girl with acute renal failure was found to have class IV systemic lupus erythematosus (SLE) nephritis on renal biopsy. A decision was taken to start her on the routine National Institute of Health protocol of pulsed methyl-prednisolone and monthly intravenous cyclophosphamide (CYC) (0.5–1.0 g/m2 of body surface area). With her post-pubertal status and the possibility of CYC induced gonadal toxicity, the question was raised as to whether she should be put on gonadotropin releasing hormone analogue (GnRH-a) therapy for ovarian protection.

STRUCTURED CLINICAL QUESTION

In young female patients with SLE undergoing CYC therapy [patient], does the use of GnRH-a [intervention], when compared to no intervention [comparison], prevent premature ovarian failure [outcome]?

SEARCH STRATEGY

[Lupus or Systemic lupus erythematosus] AND [cyclophosphamide] AND [gonadal toxicity or premature ovarian failure or fertility] AND [gonadotropin releasing hormone analogue or GnRH or GnRH-a] Limits: English, Human

Cochrane Library: None relevant

Medline: 1950–to date; EMBASE: 1974–to date; CINAHL: 1982–to date via Dialog DataStar

The search was conducted independently by both authors between December 2006 and January …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.